XFOR: X4 Pharmaceuticals, Inc Price to Sales
X4 Pharmaceuticals (XFOR) integrates ESG principles and bioethics into the development of immunological agents. The company's P/S ratio visualizes the market valuation of revenue, where 18.70 represents the latest level. Despite the risk of pressure from corporate behemoths, the business maintains monopoly potential within the rare disease niche, strengthening its R&D core through the active recruitment of specialized experts.
XFOR (X4 Pharma): analytical breakdowns and indicator data
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
- net income and valuation multiples indicators:
XFOR - Net Income|Projected Future Earnings X4 Pharmaceuticals|XFOR - P/E Multiple|Forward P/E Multiple X4 Pharmaceuticals Inc.|XFOR - Price/Earnings to Growth Multiple|EV/EBITDA Multiple X4 Pharma|XFOR - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months X4 Pharmaceuticals|XFOR - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months x4pharma.com|XFOR - Net earnings per one share growth for the current year|Earnings growth forecast for next year X4 Pharmaceuticals
- sales and revenue data:
Basic company analysis:XFOR x4pharma.com
Investors must identify fundamental value drivers through the ratio of market capitalization to annual revenue. This coefficient measures the premium the market is willing to pay per unit of sales, visualizing the normalized P/S of the company. The trend of this indicator reflects expectations regarding business efficiency. For X4 Pharmaceuticals (XFOR), such a valuation confirms the capitalization of innovations in sustainable immunological drug production and strict adherence to bioethics.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA: Market Cap to Revenue|PTGX (Protagonist Corp) - Market Cap to Revenue Ratio|Market Cap to Revenue Ratio Immunovant, Inc.|Market Cap to Revenue kiniksa.com|GRFS - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio ADPT|CLDX - Price-to-Sales Ratio|P/S Multiple Aurinia Corp (AUPH)|Market Capitalization-to-Revenue Ratio BioCryst|P/S Multiple veratx.com VERA|Dianthus Therapeutics, Inc. - P/S Multiple|PHVS: Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio AbCellera Biologics Inc ABCL|TRML (Tourmaline) - Price-to-Revenue Ratio|Market Cap to Revenue PGEN|P/S Multiple pharming.com|P/S Multiple NKTR|P/S Multiple Upstream Bio, Inc. (UPB)|Zenas Biopharma, Inc. - Market Cap to Revenue|P/S Multiple Immunome Bio IMNM|GOSS (Gossamer Bio, Inc.) - Price to Sales|kalvista.com (KALV) - Market Cap to Revenue|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharma|Savara Corp (SVRA) - Market Cap to Sales Volume|P/S Multiple Rigel Corp|ANAB (AnaptysBio, Inc.) - Price-to-Revenue Coefficient|P/S Multiple astriatx.com (ATXS)|enGene - Market Cap to Revenue|P/S Multiple RAPT Therapeutics Inc. RAPT|Aerovate - P/S Multiple|ACRS: Price-to-Revenue Ratio|Kyverna Therapeutics (KYTX) - Price-to-Revenue Ratio|TLSA (tizianalifesciences.com) - Price-to-Revenue Ratio|CABA: Price-to-Revenue Coefficient|Market Cap to Revenue Ventyx Biosciences Inc. (VTYX)|Market Cap to Revenue Ratio Theratechnologies Inc THTX|P/S Multiple Avalo Therapeutics Inc (AVTX)|Eledon Pharmaceuticals (ELDN) - Price-to-Sales Ratio|agenusbio.com - Price-to-Revenue Ratio|CLYM (Climb Bio) - Price to Sales|ZURA: Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio aTyr ATYR|ADAG (Adagene Inc.) - Price-to-Revenue Ratio|Price-to-Sales Ratio ImageneBio IMA|P/S Multiple Shattuck Therapeutics|Equillium, Inc. (EQ) - Market Capitalization-to-Revenue Ratio|P/S Multiple connectbiopharm.com (CNTB)|P/S Multiple IMUX (Immunic)|Atara Biotherapeutics, Inc. - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio InflaRx GmbH (IFRX)|ACET: Price-to-Revenue Ratio|CELU (celularity.com) - Market Cap to Revenue|INmune Bio Inc (INMB) - P/S Multiple|BRNS (Barinthus Bio) - P/S Multiple|Market Cap to Revenue Kezar Life Sciences Inc (KZR)|SAB Biotherapeutics (SABS) - Market Capitalization-to-Revenue Ratio|P/S Multiple akaritx.com (AKTX)|Price-to-Revenue Coefficient ENLV|Q32 Bio Inc - Price-to-Revenue Ratio|GOVX: Market Cap to Revenue|EDSA: Price-to-Revenue Ratio|IBIO (iBio, Inc.) - Market Cap to Revenue|Market Cap to Revenue Carisma Therapeutics Inc.|XTLB (XTL Biopharmaceuticals Ltd.) - P/S Multiple|Price-to-Revenue Ratio BOLT|Market Cap to Revenue Ratio HCW Biologics Inc. HCWB|P/S Multiple aptevotherapeutics.com (APVO)|AIM: Price to Sales|ADTX - Market Cap to Revenue|GRI Bio (GRI) - Market Cap to Revenue Ratio|XRTX (XORTX Therapeutics Inc) - Market Cap to Revenue Ratio|HIND (ReShape Lifesciences) - Market Cap to Revenue|Revelation Biosciences Corp - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Indaptus Therapeutics|scinai.com - Price-to-Sales Ratio|P/S Multiple CALI|AFMD (affimed.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple ALLK (Allakos)|P/S Multiple HOOKIPA Pharma, Inc. HOOK|IGMS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ITOS (iteostherapeutics.com)|Ocean Biomedical (OCEA) - Price-to-Revenue Ratio|Market Cap to Revenue TC BioPharm (Holdings) Plc|THRD (Third Harmonic Bio, Inc) - P/S Multiple
